| abstract |
The disclosure relates to diagnosis and/or prognosis of type 2 diabetes (T2DM) in relation to obesity and prediction of response to treatment for T2DM. The determination of a patient's risk of developing T2DM and/or the prediction of a subject's response to treatment for T2DM is based on a biomarker profile comprising at least one of the genes COX4I1, COX10, PTGS1, PTGS2, and SOD2. The gene(s) may be measured in monocytes, or microvesicles derived from monocytes, or cells derived from white or brown adipose tissues. |